Styrylquinoline Derivatives as IGF1R Inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Glioblastoma multiforme is an aggressive brain tumor with limited treatment options.
• Tyrosine kinase signaling pathways are crucial in glioblastoma progression.
• Styrylquinoline derivatives have demonstrated antiproliferative activity.

Purpose of the Study:

• To investigate the tyrosine kinase inhibitory potential of styrylquinoline analogues.
• To establish structure-activity relationships for antiproliferative effects against glioblastoma.
• To identify specific receptor tyrosine kinase targets for these compounds.

Main Methods:

• Synthesis and screening of styrylquinoline analogues for antiproliferative activity.
• Structure-activity relationship analysis based on substituent effects (OH, NO2, F, OAc).
• Screening against a panel of receptor tyrosine kinases and molecular docking simulations.

Main Results:

• Styrylquinoline derivatives exhibit significant antiproliferative activity against glioblastoma.
• Hydroxyl (OH) and nitro (NO2) substituents enhanced activity, while fluorine (F) and acetate (OAc) reduced it.
• Compounds showed high potential as insulin-like growth factor 1 receptor (IGF-1R) inhibitors, supported by molecular docking studies.

Conclusions:

• Styrylquinoline derivatives are promising candidates for glioblastoma treatment.
• Targeting the insulin-like growth factor 1 receptor (IGF-1R) pathway with these analogues offers a potential therapeutic strategy.
• Further development of these compounds could lead to novel glioblastoma therapies.